GLPwatch
GLP-1 receptor agonists today.
Diabetes Res Clin Pract · 2011
Last updated 2026-05-28GLP-1 receptor agonists are a newer class of drugs for type 2 diabetes, which affects about 257 million people worldwide. These drugs may help improve blood sugar control better than some older treatments and could reduce the risk of diabetes-related complications. The review covers approved GLP-1 drugs, those still in development, and how they might be used early in treatment or alongside insulin.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2011 |
|---|---|
| Citations | 15 |
| Relative citation ratio | 0.49 |
| NIH percentile | 29 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Heart Failure |
Abstract
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications. An emerging class of diabetes therapeutics, the glucagon-like peptide-1 (GLP-1) receptor agonists, appear to address many of the unmet needs of patients with T2DM. This review summarises the recent findings and current clinical guidelines of the currently approved GLP-1 receptor agonists and explores the new GLP-1 receptor agonists in development. It also concentrates on the physiological basis for early use of GLP-1 receptor agonists, their use as an alternative to insulin therapy, the rationale for combining them with insulin and their cost-effectiveness.
Verbatim abstract via PubMed 21767888 ↗